The NRF2, thioredoxin, and glutathione system in tumorigenesis and anticancer therapies
Cancer remains an elusive, highly complex disease and a global burden. Constant change
by acquired mutations and metabolic reprogramming contribute to the high inter-and …
by acquired mutations and metabolic reprogramming contribute to the high inter-and …
Esophageal carcinoma: towards targeted therapies
A Fatehi Hassanabad, R Chehade, D Breadner… - Cellular Oncology, 2020 - Springer
Background Patients with esophageal cancer are confronted with high mortality rates.
Whether it is esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma …
Whether it is esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma …
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Y Nakamura, H Taniguchi, M Ikeda, H Bando, K Kato… - Nature medicine, 2020 - nature.com
Comprehensive genomic profiling enables genomic biomarker detection in advanced solid
tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we …
tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we …
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression
How tumor cells genetically lose antigenicity and evade immune checkpoints remains
largely elusive. We report that tissue-specific expression of the human long noncoding RNA …
largely elusive. We report that tissue-specific expression of the human long noncoding RNA …
[HTML][HTML] Comprehensive analysis of genetic ancestry and its molecular correlates in cancer
We evaluated ancestry effects on mutation rates, DNA methylation, and mRNA and miRNA
expression among 10,678 patients across 33 cancer types from The Cancer Genome Atlas …
expression among 10,678 patients across 33 cancer types from The Cancer Genome Atlas …
Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence
Esophageal squamous cell carcinoma (ESCC) shows remarkable variation in incidence that
is not fully explained by known lifestyle and environmental risk factors. It has been …
is not fully explained by known lifestyle and environmental risk factors. It has been …
[HTML][HTML] Integrated analysis of genetic ancestry and genomic alterations across cancers
Disparities in cancer care have been a long-standing challenge. We estimated the genetic
ancestry of The Cancer Genome Atlas patients, and performed a pan-cancer analysis on the …
ancestry of The Cancer Genome Atlas patients, and performed a pan-cancer analysis on the …
Progenitor-like exhausted SPRY1+ CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma
Neoadjuvant immune checkpoint blockade (ICB) demonstrates promise in operable
esophageal squamous cell carcinoma (ESCC), but lacks available efficacy biomarkers …
esophageal squamous cell carcinoma (ESCC), but lacks available efficacy biomarkers …
[HTML][HTML] Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
L La Fleur, E Falk-Sörqvist, P Smeds, A Berglund… - Lung cancer, 2019 - Elsevier
Objectives Non-small cell lung cancer (NSCLC) is a heterogeneous disease with unique
combinations of somatic molecular alterations in individual patients, as well as significant …
combinations of somatic molecular alterations in individual patients, as well as significant …
Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1–expressing esophageal squamous cell …
PURPOSE Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line
treatment for high programmed cell death ligand 1 (PD-L1)–expressing esophageal …
treatment for high programmed cell death ligand 1 (PD-L1)–expressing esophageal …